1887

Chapter 9 : Viral Hemorrhagic Fevers

MyBook is a cheap paperback edition of the original book and will be sold at uniform, low price.

Ebook: Choose a downloadable PDF or ePub file. Chapter is a downloadable PDF file. File must be downloaded within 48 hours of purchase

Buy this Chapter
Digital (?) $30.00

Preview this chapter:
Zoom in
Zoomout

Viral Hemorrhagic Fevers, Page 1 of 2

| /docserver/preview/fulltext/10.1128/9781555819439/9781555819422.ch9-1.gif /docserver/preview/fulltext/10.1128/9781555819439/9781555819422.ch9-2.gif

Abstract:

The term viral hemorrhagic fever (VHF) designates a syndrome resulting from infection with any of at least 30 different RNA viruses from four different taxonomic families (Table 1). Although they differ in certain features, all types of VHF are characterized by fever and malaise, a fall in blood pressure that can lead to shock, the development of coagulation defects that can result in bleeding, and for many VHF agents, high mortality. With the exception of dengue virus, which is maintained among human populations by mosquito transmission, all of the VHF agents persist in nature through cycles of infection in animals. In the past, therefore, the geographic range of each disease reflected that of the reservoir species. Human illness is an accidental event resulting from contact with an infected animal or its excretions or the bite of an infected arthropod. Subsequent human-to-human transmission through contact with infectious blood or secretions occurs with multiple haemorrhagic fever (HF) viruses and can cause devastating nosocomial outbreaks. Pathogenesis in humans, in most instances, only indirectly reflects the mechanisms by which the causative agent replicates in its reservoir host, but high levels of viremia are typical. Treatment is supportive for most VHFs, but progress is being made gradually in developing specific therapeutics. Vaccines are widely available for yellow fever, and recent studies indicate that effective dengue and Ebola virus vaccines are possible.

Citation: Carson G, Bray M, Roth C. 2017. Viral Hemorrhagic Fevers, p 141-150. In Richman D, Whitley R, Hayden F (ed), Clinical Virology, Fourth Edition. ASM Press, Washington, DC. doi: 10.1128/9781555819439.ch9
Highlighted Text: Show | Hide
Loading full text...

Full text loading...

References

/content/book/10.1128/9781555819439.ch9
1. Monath TP. 2008. Treatment of yellow fever. Antiviral Res 78:116124[CrossRef].[PubMed]
2. ter Meulen J, Sakho M, Koulemou K, Magassouba N, Bah A, Preiser W, Daffis S, Klewitz C, Bae HG, Niedrig M, Zeller H, Heinzel-Gutenbrunner M, Koivogui L, Kaufmann A. 2004. Activation of the cytokine network and unfavorable outcome in patients with yellow fever. J Infect Dis 190:18211827[CrossRef].[PubMed]
3. Casals J, Hoogstraal H, Johnson KM, Shelokov A, Wiebenga NH, Work TH. 1966. A current appraisal of hemorrhagic fevers in the U.S.S.R. Am J Trop Med Hyg 15:751764.[PubMed]
4. Gajdusek DC. 1962. Virus hemorrhagic fevers. Special reference to hemorrhagic fever with renal syndrome (epidemic hemorrhagic fever). J Pediatr 60:841857[CrossRef].[PubMed]
5. Myhrman G. 1951. Nephropathia epidemica a new infectious disease in northern Scandinavia. Acta Med Scand 140:5256[CrossRef].[PubMed]
6. Centers for Disease Control and Prevention (CDC). 2000. Fatal illnesses associated with a new world arenavirus—California, 1999–2000. MMWR Morb Mortal Wkly Rep 49:709711.[PubMed]
7. Briese T, Paweska JT, McMullan LK, Hutchison SK, Street C, Palacios G, Khristova ML, Weyer J, Swanepoel R, Egholm M, Nichol ST, Lipkin WI. 2009. Genetic detection and characterization of Lujo virus, a new hemorrhagic fever-associated arenavirus from southern Africa. PLoS Pathog 5:e1000455[CrossRef].[PubMed]
8. Grard G, Fair JN, Lee D, Slikas E, Steffen I, Muyembe JJ, Sittler T, Veeraraghavan N, Ruby JG, Wang C, Makuwa M, Mulembakani P, Tesh RB, Mazet J, Rimoin AW, Taylor T, Schneider BS, Simmons G, Delwart E, Wolfe ND, Chiu CY, Leroy EM. 2012. A novel rhabdovirus associated with acute hemorrhagic fever in central Africa. PLoS Pathog 8:e1002924[CrossRef].[PubMed]
9. Yu X-J, Liang MF, Zhang SY, Liu Y, Li JD, Sun YL, Zhang L, Zhang QF, Popov VL, Li C, Qu J, Li Q, Zhang YP, Hai R, Wu W, Wang Q, Zhan FX, Wang XJ, Kan B, Wang SW, Wan KL, Jing HQ, Lu JX, Yin WW, Zhou H, Guan XH, Liu JF, Bi ZQ, Liu GH, Ren J, Wang H, Zhao Z, Song JD, He JR, Wan T, Zhang JS, Fu XP, Sun LN, Dong XP, Feng ZJ, Yang WZ, Hong T, Zhang Y, Walker DH, Wang Y, Li DX. 2011. Fever with thrombocytopenia associated with a novel bunyavirus in China. N Engl J Med 364:15231532[CrossRef].[PubMed]
10. Guo CT, Lu QB, Ding SJ. 2016. Epidemiological and clinical characteristics of severe fever with thrombocytopenia syndrome (SFTS) in China: an integrated data analysis. Epidemiol Infect 144(6):13451354.
12. Bowen MD, Peters CJ, Nichol ST. 1997. Phylogenetic analysis of the Arenaviridae: patterns of virus evolution and evidence for cospeciation between arenaviruses and their rodent hosts. Mol Phylogenet Evol 8:301316[CrossRef].[PubMed]
13. Gubler DJ. 2006. Dengue/dengue haemorrhagic fever: history and current status. Novartis Found Symp 277:316, discussion 16–22, 71–73, 251–253[CrossRef].[PubMed]
14. Uyeki TM, Mehta AK, Davey RT Jr, Liddell AM, Wolf T, Vetter P, Schmiedel S, Grünewald T, Jacobs M, Arribas JR, Evans L, Hewlett AL, Brantsaeter AB, Ippolito G, Rapp C, Hoepelman AI, Gutman J Working Group of the U.S.–European Clinical Network on Clinical Management of Ebola Virus Disease Patients in the U.S. and Europe. 2016. Clinical Management of Ebola Virus Disease in the United States and Europe. N Engl J Med 374:636646[CrossRef].[PubMed]
15. Thorson A, Formenty P, Lofthouse C, Broutet N. 2016. Systematic review of the literature on viral persistence and sexual transmission from recovered Ebola survivors: evidence and recommendations. BMJ Open 6:e008859[CrossRef].[PubMed]
16. Mahanty S, Bray M. 2004. Pathogenesis of filoviral haemorrhagic fevers. Lancet Infect Dis 4:487498[CrossRef].[PubMed]
17. Zaki SR, Shieh WJ, Greer PW, Goldsmith CS, Ferebee T, Katshitshi J, Tshioko FK, Bwaka MA, Swanepoel R, Calain P, Khan AS, Lloyd E, Rollin PE, Ksiazek TG, Peters CJ. 1999. A novel immunohistochemical assay for the detection of Ebola virus in skin: implications for diagnosis, spread, and surveillance of Ebola hemorrhagic fever. Commission de Lutte contre les Epidémies à Kikwit. J Infect Dis 179(Suppl 1):S36S47[CrossRef].[PubMed]
18. Geisbert TW, Hensley LE, Larsen T, Young HA, Reed DS, Geisbert JB, Scott DP, Kagan E, Jahrling PB, Davis KJ. 2003. Pathogenesis of Ebola hemorrhagic fever in cynomolgus macaques: evidence that dendritic cells are early and sustained targets of infection. Am J Pathol 163:23472370[CrossRef].[PubMed]
19. Baskerville A, Fisher-Hoch SP, Neild GH, Dowsett AB. 1985. Ultrastructural pathology of experimental Ebola haemorrhagic fever virus infection. J Pathol 147:199209[CrossRef].[PubMed]
20. Ryabchikova EI, Kolesnikova LV, Luchko SV. 1999. An analysis of features of pathogenesis in two animal models of Ebola virus infection. J Infect Dis 179(Suppl 1):S199S202[CrossRef].[PubMed]
21. Geisbert TW, Young HA, Jahrling PB, Davis KJ, Larsen T, Kagan E, Hensley LE. 2003. Pathogenesis of Ebola hemorrhagic fever in primate models: evidence that hemorrhage is not a direct effect of virus-induced cytolysis of endothelial cells. Am J Pathol 163:23712382[CrossRef].[PubMed]
22. Ströher U, West E, Bugany H, Klenk HD, Schnittler HJ, Feldmann H. 2001. Infection and activation of monocytes by Marburg and Ebola viruses. J Virol 75:1102511033[CrossRef].[PubMed]
23. Geisbert TW, Hensley LE, Gibb TR, Steele KE, Jaax NK, Jahrling PB. 2000. Apoptosis induced in vitro and in vivo during infection by Ebola and Marburg viruses. Lab Invest 80:171186[CrossRef].[PubMed]
24. Baize S, Leroy EM, Georges-Courbot MC, Capron M, Lansoud-Soukate J, Debré P, Fisher-Hoch SP, McCormick JB, Georges AJ. 1999. Defective humoral responses and extensive intravascular apoptosis are associated with fatal outcome in Ebola virus-infected patients. Nat Med 5:423426[CrossRef].[PubMed]
25. Basler CF,. 2005. Interferon antagonists encoded by emerging RNA viruses, p 197220. In Palese P (ed), Modulation of Host Gene Expression and Innate Immunity by Viruses. Springer, Dordrecht, The Netherlands.[CrossRef]
26. Baize S, Leroy EM, Georges AJ, Georges-Courbot MC, Capron M, Bedjabaga I, Lansoud-Soukate J, Mavoungou E. 2002. Inflammatory responses in Ebola virus-infected patients. Clin Exp Immunol 128:163168[CrossRef].[PubMed]
27. Harcourt BH, Sanchez A, Offermann MK. 1998. Ebola virus inhibits induction of genes by double-stranded RNA in endothelial cells. Virology 252:179188[CrossRef].[PubMed]
28. Zaki SR, Greer PW, Coffield LM, Goldsmith CS, Nolte KB, Foucar K, Feddersen RM, Zumwalt RE, Miller GL, Khan AS, Rollin PE, Ksiazek TG, Nichol ST, Mahy BWJ, Peters CJ. 1995. Hantavirus pulmonary syndrome. Pathogenesis of an emerging infectious disease. Am J Pathol 146:552579.[PubMed]
29. Kurane I. 2007. Dengue hemorrhagic fever with special emphasis on immunopathogenesis. Comp Immunol Microbiol Infect Dis 30:329340[CrossRef].[PubMed]
30. Burt FJ, Swanepoel R, Shieh WJ, Smith JF, Leman PA, Greer PW, Coffield LM, Rollin PE, Ksiazek TG, Peters CJ, Zaki SR. 1997. Immunohistochemical and in situ localization of Crimean-Congo hemorrhagic fever (CCHF) virus in human tissues and implications for CCHF pathogenesis. Arch Pathol Lab Med 121:839846.[PubMed]
31. Lado M, Walker NF, Baker P, Haroon S, Brown CS, Youkee D, Studd N, Kessete Q, Maini R, Boyles T, Hanciles E, Wurie A, Kamara TB, Johnson O, Leather AJ. 2015. Clinical features of patients isolated for suspected Ebola virus disease at Connaught Hospital, Freetown, Sierra Leone: a retrospective cohort study. Lancet Infect Dis 15:10241033[CrossRef].[PubMed]
32. Barry M, Touré A, Traoré FA, Sako FB, Sylla D, Kpamy DO, Bah EI, Bangoura M, Poncin M, Keita S, Tounkara TM, Cisse M, Vanhems P. 2015. Clinical predictors of mortality in patients with Ebola virus disease. Clin Infect Dis 60:18211824[CrossRef].[PubMed]
33. Cournac JM, Karkowski L, Bordes J, Aletti M. 2016. Rhabdomyolysis in Ebola Virus Disease. Results of an Observational Study in a Treatment Center in Guinea. Clin Infect Dis 62(1):1923.
34. van Velden DJ, Meyer JD, Olivier J, Gear JH, McIntosh B. 1977. Rift Valley fever affecting humans in South Africa: a clinicopathological study. S Afr Med J 51:867871.[PubMed]
35. Siam AL, Meegan JM, Gharbawi KF. 1980. Rift Valley fever ocular manifestations: observations during the 1977 epidemic in Egypt. Br J Ophthalmol 64:366374[CrossRef].[PubMed]
36. Salib M, Sobhy MI. 1978. Epidemic maculopathy. Bull Ophthalmol Soc Egypt 71:103106.[PubMed]
37. Deutman AF, Klomp HJ. 1981. Rift Valley fever retinitis. Am J Ophthalmol 92:3842[CrossRef].[PubMed]
38. Mattia JG, Vandy MJ, Chang JC, Platt DE, Dierberg K, Bausch DG, Brooks T, Conteh S, Crozier I, Fowler RA, Kamara AP, Kang C, Mahadevan S, Mansaray Y, Marcell L, McKay G, O'Dempsey T, Parris V, Pinto R, Rangel A, Salam AP, Shantha J, Wolfman V, Yeh S, Chan AK, Mishra S. 2016. Early clinical sequelae of Ebola virus disease in Sierra Leone: a cross-sectional study. Lancet Infect Dis 16:331338[CrossRef].[PubMed]
39. Scott JT, Sesay FR, Massaquoi TA, Idriss BR, Sahr F, Semple MG. 2016. Post-Ebola Syndrome, Sierra Leone. Emerg Infect Dis 22:641646[CrossRef].[PubMed]
40. Beeching NJ, Fletcher TE, Hill DR, Thomson GL. 2010. Travellers and viral haemorrhagic fevers: what are the risks? Int J Antimicrob Agents 36(Suppl 1):S26S35[CrossRef].[PubMed]
41. MMWR 29th May 2015 Lassa Fever Confirmed in Death of U.S. Traveler Returning from Liberia.
42. Racsa LD, Kraft CS, Olinger GG, Hensley LE. 2016. Viral Haemorrhagic Fever Diagnostics. Clin Infect Dis 63:214219.[PubMed]
43. Martinez VP, Bellomo C, San Juan J, Pinna D, Forlenza R, Elder M, Padula PJ. 2005. Person-to-person transmission of Andes virus. Emerg Infect Dis 11:18481853[CrossRef].[PubMed]
44. Fisher-Hoch SP. 2005. Lessons from nosocomial viral haemorrhagic fever outbreaks. Br Med Bull 73–74:123137[CrossRef].[PubMed]
45. Jeffs B. 2006. A clinical guide to viral haemorrhagic fevers: Ebola, Marburg and Lassa. Trop Doct 36:14[CrossRef].[PubMed]
46. Pigott DC. 2005. Hemorrhagic fever viruses. Crit Care Clin 21:765783, vii[CrossRef]. vii. vii. vii.[PubMed]
47. Hunt L, Gupta-Wright A, Simms V, Tamba F, Knott V, Tamba K, Heisenberg-Mansaray S, Tamba E, Sheriff A, Conteh S, Smith T, Tobin S, Brooks T, Houlihan C, Cummings R, Fletcher T. 2015. Clinical presentation, biochemical, and haematological parameters and their association with outcome in patients with Ebola virus disease: an observational cohort study. Lancet Infect Dis 15:12921299[CrossRef].[PubMed]
48. Gignoux E, Azman AS, de Smet M, Azuma P, Massaquoi M, Job D, Tiffany A, Petrucci R, Sterk E, Potet J, Suzuki M, Kurth A, Cannas A, Bocquin A, Strecker T, Logue C, Pottage T, Yue C, Cabrol JC, Serafini M, Ciglenecki I. 2016. Effect of Artesunate-Amodiaquine on Mortality Related to Ebola Virus Disease. N Engl J Med 374:2332[CrossRef].[PubMed]
49. McCormick JB, King IJ, Webb PA, Scribner CL, Craven RB, Johnson KM, Elliott LH, Belmont-Williams R. 1986. Lassa fever. Effective therapy with ribavirin. N Engl J Med 314:2026[CrossRef].[PubMed]
50. Huggins JW. 1989. Prospects for treatment of viral hemorrhagic fevers with ribavirin, a broad-spectrum antiviral drug. Rev Infect Dis 11(Suppl 4):S750S761[CrossRef].[PubMed]
51. Ascioglu S, Leblebicioglu H, Vahaboglu H, Chan KA. 2011. Ribavirin for patients with Crimean-Congo haemorrhagic fever: a systematic review and meta-analysis. J Antimicrob Chemother 66:12151222[CrossRef].[PubMed]
52. Soares-Weiser K, Thomas S, Thomson G, Garner P. 2010. Ribavirin for Crimean-Congo hemorrhagic fever: systematic review and meta-analysis. BMC Infect Dis 10:207[CrossRef].[PubMed]
53. Celikbas AK, Dokuzoğuz B, Baykam N, Gok SE, Eroğlu MN, Midilli K, Zeller H, Ergonul O. 2014. Crimean-Congo hemorrhagic fever among health care workers, Turkey. Emerg Infect Dis 20:477479[CrossRef].[PubMed]
54. van Griensven J, Edwards T, de Lamballerie X, Semple MG, Gallian P, Baize S, Horby PW, Raoul H, Magassouba N, Antierens A, Lomas C, Faye O, Sall AA, Fransen K, Buyze J, Ravinetto R, Tiberghien P, Claeys Y, De Crop M, Lynen L, Bah EI, Smith PG, Delamou A, De Weggheleire A, Haba N Ebola-Tx Consortium. 2016. Evaluation of Convalescent Plasma for Ebola Virus Disease in Guinea. N Engl J Med 374:3342[CrossRef].[PubMed]
55. Maiztegui JI, Fernandez NJ, de Damilano AJ. 1979. Efficacy of immune plasma in treatment of Argentine haemorrhagic fever and association between treatment and a late neurological syndrome. Lancet 2:12161217[CrossRef].[PubMed]
56. Enria DA, Briggiler AM, Sánchez Z. 2008. Treatment of Argentine hemorrhagic fever. Antiviral Res 78:132139[CrossRef].[PubMed]
57. Frame JD, Verbrugge GP, Gill RG, Pinneo L. 1984. The use of Lassa fever convalescent plasma in Nigeria. Trans R Soc Trop Med Hyg. 78(3):31924.
58. Sissoko D. , et al, JIKI Study Group. 2016. Experimental Treatment with Favipiravir for Ebola Virus Disease (the JIKI Trial): A Historically Controlled, Single-Arm Proof-of-Concept Trial in Guinea. PLoS Med 13:e1001967[CrossRef].[PubMed]
59. Warren TK. , et al. 2016. Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys. Nature 531:381385[CrossRef].[PubMed]
60. Whitehead SS, Blaney JE, Durbin AP, Murphy BR. 2007. Prospects for a dengue virus vaccine. Nat Rev Microbiol 5:518528[CrossRef].[PubMed]
61. Henao-Restrepo AM, Longini IM, Egger M, Dean NE, Edmunds WJ, Camacho A, Carroll MW , et al. 2015. Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial. Lancet. 386(9996):857866.

Tables

Generic image for table
TABLE 1

Some epidemiological features of the principal types of VHF

Citation: Carson G, Bray M, Roth C. 2017. Viral Hemorrhagic Fevers, p 141-150. In Richman D, Whitley R, Hayden F (ed), Clinical Virology, Fourth Edition. ASM Press, Washington, DC. doi: 10.1128/9781555819439.ch9

This is a required field
Please enter a valid email address
Please check the format of the address you have entered.
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error